← Back
Data updated: Mar 10, 2026
EXELA PHARMA
CardiovascularGastroenterologyNeurology
EXELA PHARMA is a specialty pharmaceutical company focused on Cardiovascular, Gastroenterology, Neurology. Key products include GLYRX-PF.
1984
Since
20
Drugs
-
Trials
47
Approved (2yr)
Key Drugs
Recent Activity
CUPRIC CHLORIDE 2026-01-26
TRANEXAMIC ACID 2026-01-26
SODIUM BICARBONATE 2026-01-13
MAGNESIUM SULFATE 2026-01-08
Manufacturing (CMC)
FENTANYL CITRATE 2025-12-22
Labeling
FENTANYL CITRATE 2025-12-22
Labeling
FENTANYL CITRATE 2025-12-22
Labeling
VERAPAMIL HYDROCHLORIDE 2025-11-24
VERAPAMIL HYDROCHLORIDE 2025-11-13
CAFFEINE CITRATE 2025-09-26
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 44%
4 drugs
Gastroenterology 22%
2 drugs
Neurology 11%
1 drugs
Metabolic 11%
1 drugs
Infectious Disease 11%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Merck big-pharma
Infectious Disease, Cardiovascular, Metabolic
Novo Nordisk big-pharma
Metabolic, Cardiovascular, Infectious Disease, Neurology
Johnson & Johnson big-pharma
Infectious Disease, Cardiovascular, Metabolic
AZURITY specialty
Cardiovascular, Neurology, Metabolic, Infectious Disease
WARNER CHILCOTT LLC specialty
Cardiovascular, Neurology, Gastroenterology, Infectious Disease
Active (14)
Discontinued (6)
Company Info
- First Approval
- 1984-03-30
- Latest
- 2025-12-22
- Applications
- 22